Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis

被引:8
|
作者
Yun, Jan-Di [1 ]
Ha, Junghee [2 ]
Kim, Solah [1 ]
Park, Hyung Ah [1 ]
Yoo, Juyoung [1 ]
Ahn, Sung Soo [1 ]
Jung, Seung Min [1 ]
Song, Jason Jungsik [1 ,3 ]
Park, Yong-Beom [1 ,3 ]
Lee, Sang-Won [1 ,3 ]
机构
[1] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Div Rheumatol,Dept Internal Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Coll Med, Dept Psychiat, Seoul, South Korea
[3] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Antineutrophil cytoplasmic antibody-associated vasculitis; Depression; Predictor; SF-36; RHEUMATOLOGY; 1990; CRITERIA; QUALITY-OF-LIFE; GRANULOMATOSIS; PREVALENCE; SYMPTOMS; CLASSIFICATION; POLYANGIITIS; CONSENSUS; SCALE;
D O I
10.1007/s10067-019-04657-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the frequency of depressive disorders and determined the predictors of depressive disorders in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Sixty-one patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were enrolled in this study. We assessed the Birmingham vasculitis activity score (BVAS), vasculitis damage index (VDI) and the Korean version of the short form 36-item Health Survey (SF-36). SF-36 consists of the mental component score (MCS) and physical component score (PCS). Depression disorder was identified based on the Korean version of the Center for Epidemiologic Studies Depression Scale-Revised (K-CESD-R) >= 16. Mood states including depression were assessed by the Korean edition of the Profile of Mood States (K-POMS) subscales. The mean age was 62.2 years (19 men). Twenty-eight AAV patients (45.9%) had depressive disorders based on K-CESD-R >= 16. Both SF-36 MCS and SF-36 PCS were negatively correlated with K-CESD-R (r = - 0.687 and r = - 0.594) and K-POMS depression (r = - 0.604 and r = - 0.480), respectively. The optimal cut-offs of SF-36 MCS and SF-36 PCS for depressive disorders based on K-CESD-R >= 16 were obtained as 48.07 and 55.63. Patients with SF-36 MCS <= 48.07 exhibited a significantly high RR for depressive disorders, compared with those without (RR 42.667). Also, patients with SF-36 PCS <= 55.63 showed a significantly high RR depressive disorder, compared with those without (RR 13.619). We demonstrated that SF-36 could help to estimate the current depressive disorders. We also suggest a method to obtain the optimal cut-offs of SF-36 to predict depressive disorders.
引用
收藏
页码:3485 / 3491
页数:7
相关论文
共 50 条
  • [1] Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis
    Jan-Di Yun
    Junghee Ha
    Solah Kim
    Hyung Ah Park
    Juyoung Yoo
    Sung Soo Ahn
    Seung Min Jung
    Jason Jungsik Song
    Yong-Beom Park
    Sang-Won Lee
    Clinical Rheumatology, 2019, 38 : 3485 - 3491
  • [2] Classification of Antineutrophil Cytoplasmic Antibody-associated Vasculitis
    Lee, Sang-Won
    Park, Yong-Beom
    JOURNAL OF RHEUMATIC DISEASES, 2019, 26 (03): : 156 - 164
  • [3] Predictors of Mortality in Critically Ill Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Zhang, Yuqi
    Guo, Jinyan
    Zhang, Panpan
    Zhang, Lei
    Duan, Xiaoguang
    Shi, Xiaofei
    Guo, Nailiang
    Liu, Shengyun
    FRONTIERS IN MEDICINE, 2021, 8
  • [4] Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis
    Shuai, Z. W.
    Lv, Y. F.
    Zhang, M. M.
    Hu, Z. Y.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (02): : 5296 - 5303
  • [5] ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS IN
    Popescu, M. L.
    Predeteanu, D.
    Opris-Belinski, D.
    Balanescu, A.
    Berghea, F.
    Borangiu, A.
    Constantinescu, C.
    Groseanu, L.
    Ionescu, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : S27 - S28
  • [6] Patient-Reported Sinonasal Symptoms and Risk of Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Romich, Ellen
    Banerjee, Shubhasree
    Amudala, Naomi
    Chou, Sherry
    Li, Ruolan
    Lee, Hongzhe
    Cohen, Noam
    Merkel, Peter A.
    Rhee, Rennie L.
    ARTHRITIS CARE & RESEARCH, 2024, 76 (08) : 1099 - 1108
  • [7] Bronchiectasis in patients with antineutrophil cytoplasmic antibody-associated vasculitis: a case control study on clinical features and prognosis
    Ren, Jiaqi
    Ding, Yanling
    Zhao, Jinxia
    Sun, Yongchang
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2022, 16 (06) : 697 - 705
  • [8] The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey
    Pamuk, Omer Nuri
    Donmez, Salim
    Calayir, Gokce Busra
    Pamuk, Gulsum Emel
    CLINICAL RHEUMATOLOGY, 2016, 35 (08) : 2063 - 2071
  • [9] Rituximab maintenance therapy for patients with antineutrophil cytoplasmic antibody-associated vasculitis in Japan
    Takeyama, Yukiko
    Ono, Nobuyuki
    Shirahama, Yuri
    Inoue, Yasushi
    Tanaka, Atsushi
    Ueda, Naoyasu
    Nishimura, Naoya
    Nagano, Shuji
    Uchino, Ayumi
    Miyamura, Tomoya
    Oryoji, Kensuke
    Inoue, Hisako
    Maruyama, Akihito
    Ota, Shun-ichiro
    Yoshizawa, Seiji
    Sawabe, Takuya
    Himuro, Naoko
    Miyake, Katsuhisa
    Kimoto, Yasutaka
    Horiuchi, Takahiko
    Mitoma, Hiroki
    Niiro, Hiroaki
    Takamori, Ayako
    Tada, Yoshifumi
    MODERN RHEUMATOLOGY, 2021, 31 (02) : 408 - 416
  • [10] Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (01) : 1 - +